 WALTHAM, Mass.--BUSINESS WIRE--Deciphera Pharmaceuticals, Inc. NASDAQ:DCPH today announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK in patients with second-line gastrointestinal stromal tumor GIST. QINLOCK, the Companys switch-control tyrosine kinase inhibitor, is currently approved in the U.S., Canada, and Australia for patients with fourth-line GIST. We are pleased to announce the completion of target 